DelveInsight’s, “Genital Warts Pipeline Insight 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Genital Warts Treatment Landscape. Click here to read more @ Genital Warts Pipeline Outlook

Key Takeaways from the Genital Warts Pipeline Report

• On 11 August 2025, Merck Sharp & Dohme LLC announced a study includes a Base Study to assess efficacy and safety of V503, and an Extension Study. Participants who received placebo in the Base Study will be eligible to receive V503 vaccine on Day 1, Month 2, and Month 6 of the Extension Study. Participants who received less than 3 doses of V503 in the Base Study will be offered the opportunity to complete the 3-dose regimen in the Extension Study.
• DelveInsight’s Genital Warts pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Genital Warts treatment.
• The leading Genital Warts Companies such as ViroXis Corporation, bioRASI, LLC, Verrica Pharmaceuticals Inc., Orgenesis, Heber Biotec, Cassiopea, Novan, Peritech Pharma, Novartis and others.
• Promising Genital Warts Pipeline Therapies such as Imiquimod, NVN1000 8% Gel, Polyphenon E (Veregen) 15% ointment, AP611074 5% gel, Picato, V501, Podofilox Gel 0.5% and others.

Discover groundbreaking developments in Genital Warts Therapies! Gain in-depth knowledge of key Genital Warts clinical trials, emerging drugs, and market opportunities @ Genital Warts Clinical Trials Assessment

Genital Warts Emerging Drugs Profile

• VP-102: Verrica Pharmaceuticals

Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. Verrica is developing VP-102 for the treatment of common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.

• SB206: Novan

Novan is developing SB206 as a topical antiviral gel for the treatment of viral skin infections, including external genital warts (EGW) caused by human papillomavirus (HPV). SB206 exhibited a dose responsive pharmacologic effect with complete inhibition of papilloma growth compared to topical imiquimod in an in vivo model. NVN1000, the active pharmaceutical ingredient in SB206, exhibited a dose dependent decrease in HPV viral replication in human raft cell culture model.

• CB-06-02: Cassiopea

CB-06-02, a NCE, immune modulator is being developed for the treatment of genital warts. Cassiopea believes it is the first potential treatment for this condition based on tellurium, a rare element. It acts as a low-toxicity immunomodulator in supporting the natural immune response against Human Papilloma Virus, or HPV. Based on the drug profiling Cassiopea has performed to date, the Company believes CB-06-02 has the potential to have a faster onset of action and a lower recurrence rate than currently available treatments.

The Genital Warts Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Genital Warts with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Genital Warts Treatment.
• Genital Warts Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Genital Warts Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Genital Warts market

Stay informed about the Genital Warts pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Genital Warts Unmet Needs

Genital Warts Companies

ViroXis Corporation, bioRASI, LLC, Verrica Pharmaceuticals Inc., Orgenesis, Heber Biotec, Cassiopea, Novan, Peritech Pharma, Novartis, and others.

Genital Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenius
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Genital Warts Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Transform your understanding of the Genital Warts Pipeline! See the latest progress in drug development and clinical research @ Genital Warts Market Drivers and Barriers, and Future Perspectives

Scope of the Genital Warts Pipeline Report

• Coverage- Global
• Genital Warts Companies- ViroXis Corporation, bioRASI, LLC, Verrica Pharmaceuticals Inc., Orgenesis, Heber Biotec, Cassiopea, Novan, Peritech Pharma, Novartis and others.
• Genital Warts Pipeline Therapies- Imiquimod, NVN1000 8% Gel, Polyphenon E (Veregen) 15% ointment, AP611074 5% gel, Picato, V501, Podofilox Gel 0.5% and others.
• Genital Warts Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Genital Warts Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Research-Access the Full Genital Warts Pipeline Analysis Today! @ Genital Warts Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Genital Warts: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Genital Warts – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Genital Warts Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug Name: Company Name
11. Mid-Stage Products (Phase II)
12. VP-102: Verrica Pharmaceuticals
13. SB206: Novan
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Pre-clinical and Discovery Stage Products
18. Drug Name: Company Name
19. Inactive Products
20. Genital Warts Key Companies
21. Genital Warts Key Products
22. Genital Warts- Unmet Needs
23. Genital Warts- Market Drivers and Barriers
24. Genital Warts- Future Perspectives and Conclusion
25. Genital Warts Analyst Views
26. Genital Warts Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/genital-warts-pipeline-insight